References analysis of the Wikipedia article "蘭格漢氏細胞組織球增生症" in the Chinese version

doi.org (Global: 2^nd place; Chinese: 23^rd place)

Haupt R, Minkov M, Astigarraga I, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. February 2013, 60 (2): 175–84. PMID 23111991. doi:10.1002/pbc.24367.

Goyal G, Tazi A, Go RS, et al. International expert consensus recommendations for the diagnosis and treatment of Langerhans cell histiocytosis in adults. Blood. April 2022, 139 (17): 2601–21. PMC 11022927 

. PMID 35271698. doi:10.1182/blood-2021-12-389606.

Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. April 2020, 135 (16): 1319–1331. PMID 32106306. doi:10.1182/blood.2019000931.

Nanduri VR, Pritchard J, Levinsky RJ, Ball S. Long term morbidity following treatment of Langerhans' cell histiocytosis: clinical observations and results from the UK LCH study group. Eur J Pediatr. June 1996, 155 (6): 449–54. PMID 8795497. doi:10.1007/BF01953986.

Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. May 2004, 42 (5): 419–25. PMID 15054909. doi:10.1002/pbc.10437.

Donadieu J, Rolon MA, Thomas C, et al. Endocrine involvement in pediatric-onset Langerhans' cell histiocytosis: a population-based study. J Pediatr. March 2004, 144 (3): 344–50. PMID 15001938. doi:10.1016/j.jpeds.2003.12.023.

Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. June 2010, 156 (6): 873–81.e1. PMID 20227716. doi:10.1016/j.jpeds.2010.01.036.

Edgar JD, Haines SA, Donadieu J, et al. Second malignancies in Langerhans cell histiocytosis: a report from the International LCH Study Group. Pediatr Blood Cancer. April 2021, 68 (4): e28813. PMID 33314615. doi:10.1002/pbc.28813.

Krooks J, Minkov M, Wettergren B, et al. Langerhans cell histiocytosis in children: a population-based study of incidence, clinical features, treatment, and outcome. Pediatr Blood Cancer. March 2018, 65 (3): e26901. PMID 29115726. doi:10.1002/pbc.26901.

Allen CE, Merad M, McClain KL. Langerhans-Cell Histiocytosis. N Engl J Med. August 2018, 379 (9): 856–68. PMC 6334777 

. PMID 30157397. doi:10.1056/NEJMoa1802472.

Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. September 2010, 116 (11): 1919–23. PMC 2947417 

. PMID 20519626. doi:10.1182/blood-2010-04-277703.

Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. November 2014, 124 (19): 3007–15. PMC 4224201 

. PMID 25202140. doi:10.1182/blood-2014-05-577825.

Lorillon G, Tazi A. Adult pulmonary Langerhans cell histiocytosis. Curr Opin Pulm Med. September 2017, 23 (5): 449–56. PMID 28604536. doi:10.1097/MCP.0000000000000404.

Vassallo R, Ryu JH. Pulmonary Langerhans' cell histiocytosis. Clin Chest Med. March 2012, 33 (1): 131–46. PMID 22310464. doi:10.1016/j.ccm.2011.11.001.

Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J. June 2006, 27 (6): 1272–85. PMID 16738347. doi:10.1183/09031936.06.00024005.

Griffin GK, Sholl LM, Lindeman NI, et al. Targeted therapy in histiocytosis: clinical application of molecular data and emerging biomarkers. J Natl Compr Canc Netw. December 2020, 18 (12): 1722–30. PMID 33285511. doi:10.6004/jnccn.2020.7637.

Gadner H, Minkov M, Grois N, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. June 2013, 121 (25): 5006–14. PMID 23613528. doi:10.1182/blood-2012-09-455774.

Salotti JA, Nanduri V, Pearce MS, Parker L, Lynn R, Windebank KP. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child. May 2009, 94 (5): 376–80. PMID 19174413. doi:10.1136/adc.2008.144713.

Guyot-Goubin A, Donadieu J, Barkaoui M, Bellec S, Thomas C, Clavel J. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000–2004. Pediatr Blood Cancer. July 2008, 51 (1): 71–75. PMID 18383380. doi:10.1002/pbc.21501.

Stålemark H, Laurencikas E, Karis J, Gavhed D, Fadeel B, Henter JI. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer. July 2008, 51 (1): 76–81. PMID 18383381. doi:10.1002/pbc.21502.

Goyal G, Young JR, Koster MJ, et al. The Mayo Clinic Histiocytosis Working Group consensus statement for the diagnosis and evaluation of adult patients with histiocytic neoplasms: Erdheim-Chester disease, Langerhans cell histiocytosis, and Rosai-Dorfman disease. Mayo Clin Proc. October 2019, 94 (10): 2054–71. PMID 31582245. doi:10.1016/j.mayocp.2019.03.017.

Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. June 2016, 127 (22): 2672–81. PMID 26994086. doi:10.1182/blood-2016-01-690636.

Brown NA, Furtado LV, Betz BL, et al. High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis. Blood. September 2014, 124 (10): 1655–58. PMID 25053681. doi:10.1182/blood-2014-05-577312.

Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. February 2016, 6 (2): 154–65. PMC 4744516 

. PMID 26681714. doi:10.1158/2159-8290.CD-15-0913.

Go H, Jeon YK, Park S, et al. ALK-positive histiocytosis: a new clinicopathologic spectrum distinct from Langerhans cell histiocytosis. Blood. January 2016, 127 (2): 259–61. PMID 26644138. doi:10.1182/blood-2015-11-681999.

Chang K, Tay A, Kuick CH, et al. ALK-positive histiocytosis: an expanded clinicopathologic spectrum. Haematologica. February 2019, 104 (2): e100–e103. PMC 6355491 

. PMID 30337404. doi:10.3324/haematol.2018.205456. 温哥华格式错误 (帮助)

Berres ML, Lim K, Peters T, et al. BRAF-V600E expression in precursor cells identifies divergent human LCH teaching programs. Science. September 2014, 345 (6204): 1619–23. PMID 25170053. doi:10.1126/science.1256992. 温哥华格式错误 (帮助)

Milne P, Bigley V, Bacon CM, et al. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. July 2017, 130 (2): 167–75. PMC 5510791 

. PMID 28473486. doi:10.1182/blood-2016-12-757795.

Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood. March 2001, 97 (5): 1241–48. PMID 11222366. doi:10.1182/blood.v97.5.1241.

Emile JF, Chetritt J, Fraitag S, et al. Langerhans cell histiocytosis cells are activated Langerhans cells. J Pathol. October 1995, 177 (2): 171–76. PMID 8523080. doi:10.1002/path.1711770210. 引用错误：带有name属性“Emile1995”的<ref>标签用不同内容定义了多次

Durham BH, Roos-Weil D, Bauman T, et al. Clonal architecture of Langerhans cell histiocytosis and Erdheim-Chester disease. Blood. March 2019, 133 (10): 1127–31. PMC 6405338 

. PMID 30602584. doi:10.1182/blood-2018-11-886412.

Papo M, Diamond EL, Cohen-Aubart F, Emile JF, Roos-Weil D, Gupta N, Durham BH, Ozkaya N, Dogan A, Ulaner GA, Rampal R, Kahn JE, Sené T, Charlotte F, Hervier B, Besnard C, Bernard OA, Settegrana C, Droin N, Hélias-Rodzewicz Z, Amoura Z, Abdel-Wahab O, Haroche J. High prevalence of myeloid neoplasms in adults with non-Langerhans cell histiocytosis. Blood. August 2017, 130 (8): 1007–1013. PMC 5570678 

. PMID 28679734. doi:10.1182/blood-2017-03-772190.

Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs. 2011, 13 (2): 75–86. PMID 21401219. doi:10.2165/11586960-000000000-00000.

Elia D, Torre O, Cassandro R, et al. Pulmonary Langerhans cell histiocytosis: a comprehensive analysis of 40 patients and literature review. Eur J Intern Med. June 2015, 26 (5): 351–58. PMID 25982979. doi:10.1016/j.ejim.2015.04.011.

Prosch H, Grois N, Prayer D, et al. Central diabetes insipidus as presenting symptom of Langerhans cell histiocytosis. Pediatr Blood Cancer. November 2004, 43 (5): 594–99. PMID 15390306. doi:10.1002/pbc.20130.

Grois N, Prayer D, Prosch H, Minkov M, Potschger U, Gadner H. Course and clinical impact of magnetic resonance imaging findings in neurodegenerative Langerhans cell histiocytosis. Pediatr Blood Cancer. December 2009, 53 (7): 1255–60. PMID 19731323. doi:10.1002/pbc.22235.

Kemps PG, Picarsic J, Durham BH, et al. ALK-positive histiocytosis: a new clinicopathologic entity with molecular diversity and single-agent ALK inhibitor efficacy. Blood Adv. February 2022, 6 (4): 1157–70. PMC 8866007 

. PMID 34710297. doi:10.1182/bloodadvances.2021005538.

Yeh EA, Greenberg J, Abla O, Longoni G, Diamond E, Hermiston M, Tran B, Rodriguez-Galindo C, Allen CE, McClain K, North American Consortium for H. Evaluation and treatment of Langerhans cell histiocytosis patients with central nervous system abnormalities: Current views and new vistas. Pediatr Blood Cancer. January 2018, 65 (1). PMID 28944988. doi:10.1002/pbc.26784. 温哥华格式错误 (帮助)

Eckstein O, Pötschger U, Grois N, et al. Vincristine and prednisone for the treatment of Langerhans cell histiocytosis with single-system-multifocal bone disease: a multicenter retrospective analysis. Pediatr Blood Cancer. May 2019, 66 (5): e27643. PMID 30688018. doi:10.1002/pbc.27643.

Donadieu J, Bernard F, van Noesel M, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. September 2015, 126 (12): 1415–23. PMID 26188000. doi:10.1182/blood-2015-03-635151.

Simko SJ, Tran HD, Jones J, et al. Clofarabine salvage therapy in refractory Langerhans cell histiocytosis. Pediatr Blood Cancer. February 2014, 61 (2): 306–17. PMID 24106081. doi:10.1002/pbc.24798.

Cantu MA, Lupo PJ, Bilgi M, et al. Optimal therapy for adults with Langerhans cell histiocytosis: a systematic review. Cancer. December 2012, 118 (23): 5691–700. PMID 22510827. doi:10.1002/cncr.27623.

Pardanani A, Phyliky RL, Li CY, Tefferi A. 2-Chlorodeoxyadenosine therapy for disseminated Langerhans cell histiocytosis. Mayo Clin Proc. March 2003, 78 (3): 301–06. PMID 12630580. doi:10.4065/78.3.301.

Adam Z, Szturz P, Pour L, Krejčí M, Koukalová R, Řehák Z, et al. [Cytarabine treatment for Langerhans cell histiocytosis in 21 adult patients in the Czech Republic]. Klin Onkol. 2015, 28 (5): 348–54. PMID 26479433. doi:10.14735/amko2015348 （Czech）.

Maia RC, de Rezende LM, Robaina M, et al. CHOP chemotherapy for adult Langerhans cell histiocytosis: a case report and review of the literature. Hematol Oncol Stem Cell Ther. December 2010, 3 (4): 190–94. PMID 21220225. doi:10.1016/s1658-3876(10)50030-x.

Derenzini E, Fina MP, Stefoni V, et al. MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. Ann Oncol. June 2010, 21 (6): 1173–78. PMID 19910353. doi:10.1093/annonc/mdp508.

Haroche J, Cohen-Aubart F, Emile JF, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. June 2012, 119 (24): 5691–93. PMID 22563090. doi:10.1182/blood-2012-03-419531.

Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis analysis of data from the histology-independent VE-BASKET study. JAMA Oncol. March 2018, 4 (3): 384–88. PMC 5885849 

. PMID 29222555. doi:10.1001/jamaoncol.2017.5029.

Héritier S, Hélias-Rodzewicz Z, Lapillonne H, et al. Vemurafenib use in children with refractory BRAFV600E-positive Langerhans cell histiocytosis: the French nationwide experience. Blood Adv. May 2021, 5 (10): 2171–75. PMC 8155775 

. PMID 33974066. doi:10.1182/bloodadvances.2020003915.

Donadieu J, Larabi IA, Tardieu M, et al. Vemurafenib for refractory multisystem Langerhans cell histiocytosis in children: an international observational study. J Clin Oncol. November 2019, 37 (31): 2857–65. PMID 31509521. doi:10.1200/JCO.19.00451.

Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. August 2015, 373 (8): 726–36. PMC 4971773 

. PMID 26287849. doi:10.1056/NEJMoa1502309.

Suh MR, Lee J, Lee J, et al. Dabrafenib and trametinib in pediatric patients with BRAF V600-mutant high-grade glioma. Clin Cancer Res. April 2022, 28 (7): 1394–401. PMID 35086871. doi:10.1158/1078-0432.CCR-21-3479.

Cohen Aubart F, Charlotte F, Mir O, et al. Sustained response to the combination of dabrafenib and trametinib in BRAF V600E-mutated adult Langerhans cell histiocytosis. Haematologica. September 2018, 103 (9): e424–e426. PMC 6119159 

. PMID 29773581. doi:10.3324/haematol.2018.191417.

Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. March 2019, 567 (7749): 521–24. PMC 6438706 

. PMID 30867592. doi:10.1038/s41586-019-1012-y.

Cohen-Aubart F, Emile JF, Maksud P, et al. Efficacy and safety of MEK inhibition in Langerhans cell histiocytosis and Erdheim-Chester disease. Blood. October 2021, 138 (17): 1515–19. PMID 34293062. doi:10.1182/blood.2021011747.

Bouayed S, Delord M, Heiblig M, et al. Cobimetinib effectiveness and tolerance in eight refractory BRAF V600E-mutated Langerhans cell histiocytosis patients. Br J Haematol. June 2021, 193 (4): 824–28. PMID 33882146. doi:10.1111/bjh.17474.

Heiblig M, Bouayed S, Maucort-Boulch D, et al. Efficacy and safety of MEK inhibitors in adult Langerhans cell histiocytosis. Blood Adv. January 2022, 6 (1): 129–33. PMC 8753210 

. PMID 34710299. doi:10.1182/bloodadvances.2021005611.

Shanmugam V, Griffin GK, Jacobsen ED, et al. Durable responses in patients with histiocytoses harboring activating ALK alterations. Blood Adv. August 2021, 5 (16): 3249–53. PMC 8387004 

. PMID 34410300. doi:10.1182/bloodadvances.2021004841.

Rossi S, Gasparini P, Cascione L, et al. ALK-rearranged histiocytosis: report of two cases responding to ALK inhibitors. J Natl Cancer Inst. October 2019, 111 (10): 1097–100. PMID 30689840. doi:10.1093/jnci/djy233.

Cohen Aubart F, Emile JF, Carrat F, et al. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the TAILORED study). Blood. September 2017, 130 (11): 1377–80. PMID 28705886. doi:10.1182/blood-2017-03-775979.

nih.gov (Global: 4^th place; Chinese: 5^th place)

ncbi.nlm.nih.gov

. PMID 35271698. doi:10.1182/blood-2021-12-389606.

Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. April 2020, 135 (16): 1319–1331. PMID 32106306. doi:10.1182/blood.2019000931.

Grois N, Fahrner B, Arceci RJ, et al. Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. June 2010, 156 (6): 873–81.e1. PMID 20227716. doi:10.1016/j.jpeds.2010.01.036.

Allen CE, Merad M, McClain KL. Langerhans-Cell Histiocytosis. N Engl J Med. August 2018, 379 (9): 856–68. PMC 6334777 

. PMID 30157397. doi:10.1056/NEJMoa1802472.

Badalian-Very G, Vergilio JA, Degar BA, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. September 2010, 116 (11): 1919–23. PMC 2947417 

. PMID 20519626. doi:10.1182/blood-2010-04-277703.

. PMID 25202140. doi:10.1182/blood-2014-05-577825.

Lorillon G, Tazi A. Adult pulmonary Langerhans cell histiocytosis. Curr Opin Pulm Med. September 2017, 23 (5): 449–56. PMID 28604536. doi:10.1097/MCP.0000000000000404.

Vassallo R, Ryu JH. Pulmonary Langerhans' cell histiocytosis. Clin Chest Med. March 2012, 33 (1): 131–46. PMID 22310464. doi:10.1016/j.ccm.2011.11.001.

Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J. June 2006, 27 (6): 1272–85. PMID 16738347. doi:10.1183/09031936.06.00024005.

Diamond EL, Durham BH, Haroche J, et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov. February 2016, 6 (2): 154–65. PMC 4744516 

. PMID 26681714. doi:10.1158/2159-8290.CD-15-0913.

Chang K, Tay A, Kuick CH, et al. ALK-positive histiocytosis: an expanded clinicopathologic spectrum. Haematologica. February 2019, 104 (2): e100–e103. PMC 6355491 

. PMID 30337404. doi:10.3324/haematol.2018.205456. 温哥华格式错误 (帮助)

Milne P, Bigley V, Bacon CM, et al. Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults. Blood. July 2017, 130 (2): 167–75. PMC 5510791 

. PMID 28473486. doi:10.1182/blood-2016-12-757795.

Geissmann F, Lepelletier Y, Fraitag S, et al. Differentiation of Langerhans cells in Langerhans cell histiocytosis. Blood. March 2001, 97 (5): 1241–48. PMID 11222366. doi:10.1182/blood.v97.5.1241.

Durham BH, Roos-Weil D, Bauman T, et al. Clonal architecture of Langerhans cell histiocytosis and Erdheim-Chester disease. Blood. March 2019, 133 (10): 1127–31. PMC 6405338 

. PMID 30602584. doi:10.1182/blood-2018-11-886412.

. PMID 28679734. doi:10.1182/blood-2017-03-772190.

Minkov M. Multisystem Langerhans cell histiocytosis in children: current treatment and future directions. Paediatr Drugs. 2011, 13 (2): 75–86. PMID 21401219. doi:10.2165/11586960-000000000-00000.

Prayer D, Grois N, Prosch H, Gadner H, Barkovich AJ. MR imaging presentation of neurodegenerative Langerhans cell histiocytosis. AJNR Am J Neuroradiol. May 2004, 25 (5): 880–91. PMC 7974775 

. PMID 15140738.

. PMID 34710297. doi:10.1182/bloodadvances.2021005538.

Saven A, Burian C. Cladribine activity in adult Langerhans-cell histiocytosis. Blood. June 1999, 93 (12): 4125–30. PMID 10361113.

Adam Z, Szturz P, Vaníček J, et al. Cladribine (2-chlorodeoxyadenosine) in the treatment of 33 patients with Langerhans cell histiocytosis. Vnitr Lek. Fall 2017, 63 (11): 844–52. PMID 29228807.